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Abstract: Asthma is a complex chronic inflammatory disease of multifactorial etiology. 
International guidelines increasingly recognize that a standard “one size fits all” approach 
is no longer an effective approach to achieve optimal treatment outcomes, and a number of 
disease phenotypes have been proposed for asthma, which has the potential to guide treatment 
decisions. Among the many asthma phenotypes, allergic asthma represents the widest and 
most easily recognized asthma phenotype, present in up to two-thirds of adults with asthma. 
Immunoglobulin E (IgE) production is the primary and key cause of allergic asthma leading to 
persistent symptoms, exacerbations and a poor quality of life. Therefore, limiting IgE activity 
upstream could stop the entire allergic inflammation cascade in IgE-mediated allergic asthma. 
The anti-IgE treatment omalizumab has an accepted place in the management of severe asthma 
(Global Initiative for Asthma [GINA] step 5) and represents the first (and, currently, only) 
targeted therapy with a specific target in severe allergic asthma. This review summarizes cur-
rent knowledge of the mechanisms and pathogenesis of severe asthma, examines the actual role 
of IgE in asthma and the biological rationale for targeting IgE in allergic asthma and reviews 
the data for the efficacy and safety of omalizumab in the treatment of severe asthma. Current 
knowledge of the role of IgE in asthma, extensive clinical trial data and a decade of use in clinical 
practice has established omalizumab as a safe and effective targeted therapy for the treatment 
of patients with severe persistent IgE-mediated allergic asthma.
Keywords: anti-immunoglobulin E, allergic asthma, Global Initiative for Asthma step 5 therapy, 
severe persistent asthma, omalizumab, phenotypes, targeted therapy
Introduction
Asthma is now considered an inflammatory chronic disease of multifactorial etiology. 
Initially, asthma was described as a typical eosinophilic airway inflammation, often 
sustained by allergic sensitization, which led to bronchial hyperresponsiveness and 
acute bronchoconstriction in response to specific and nonspecific triggers.1 Later on, 
it became clearer that different inflammatory and noninflammatory mechanisms may 
be responsible for the development and progression of asthma; airway neutrophilic 
inflammation has been described in subgroups of asthmatic patients,2 particularly 
those with severe asthma,3 and also a paucigranulocytic airway inflammation has 
been reported in some asthma phenotypes, such as asthmatics with obesity and/or 
gastro-esophageal reflux.4 This “non-eosinophilic” inflammatory phenotype seems 
fairly stable over time.2,5 This led to the opinion that “the common disease asthma is 
probably not a single disease, but rather a complex of multiple, separate syndromes 
that overlap”.6
According to this view, the new Global Initiative for Asthma (GINA) strategy 
document for asthma management and prevention defines the condition as a 
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“heterogeneous disease, usually characterized by chronic 
airway inflammation”, with the presence of respiratory symp-
toms and functional abnormalities.7 This heterogeneity may 
be related to the inducing mechanisms and triggers (allergic 
vs nonallergic), the pathologic background (eosinophilic vs 
non-eosinophilic inflammation), the clinical manifestations 
(in terms of severity, frequency of exacerbations, response 
to treatment) and the outcomes (remission or progression 
to non-reversible airway obstruction). Several associated 
conditions or comorbidities (upper airway diseases, obesity, 
smoking habit, etc) may modify the clinical expression of the 
disease. A major consequence of this new asthma definition is 
that, in light of the poor specificity of symptoms, risk factors 
and pathologic background, pulmonary function assessment 
now plays a crucial role in the diagnosis of the disease; in 
particular, the wide variability over time of forced expiratory 
volume in 1 second (FEV
1
) may be now considered the main 
diagnostic criterion for asthma.
The goal of treatment in patients with asthma is to achieve 
a good control of symptoms and to reduce the “future risk”, as 
expressed by the risk of future exacerbations, loss of asthma 
control, progressive decline in pulmonary function or drug-
related side effects.8 All international guidelines suggest to 
adapt the level of treatment to the level of severity/control 
of the disease7,9,10 using a standard approach, which has been 
demonstrated as effective in the large majority of unselected 
asthmatic patients. However, a “one-size-fits-all” therapeutic 
strategy no longer appears appropriate to effectively pursue 
these goals, given the heterogeneity of disease. Furthermore, 
although patients with severe disease represent only 5%–10% 
of the total number of subjects with asthma, this small popula-
tion consumes a disproportionate amount of the global asthma 
budget (~50%) due to unscheduled health care utilization in 
primary care, hospitalizations due to severe exacerbations 
and the costs of pharmacotherapy.11,12 For this reason, a great 
deal of attention has been focused in the last few years toward 
better assessment and management of patients with severe 
asthma. This approach has been clearly mentioned in the new 
GINA document,7 where, when population-level decisions 
about asthma treatment are under consideration, the outlined 
“preferred option” to be taken at each step represents the 
best treatment for most patients, based on the best available 
evidence from the efficacy, effectiveness and safety data 
of randomized controlled trials, meta-analyses and obser-
vational studies, together with considerations of net cost. 
However, treatment decisions for individual patients should 
also consider any patient characteristics or phenotype that is 
able to predict the patient’s likely response to treatment, in 
addition to patient preferences and practical issues such as 
inhaler technique, adherence and the cost to the patient.7
In line with the concept of the heterogeneity of asthma, a 
number of disease phenotypes have been proposed over the 
recent years, also taking into account the different inflam-
matory origins of the disease (Table 1).6 Phenotypes can 
play a role in guiding treatment decisions. Several examples 
may be described: omalizumab in severe allergic asthma, 
allergen immunotherapy in allergic asthmatics,13 montelu-
kast in asthma plus allergic rhinitis or exercise-induced 
asthma14 and tiotropium in severe asthmatics with persis-
tent bronchoconstriction.15 This is particularly relevant in 
more severe categories of asthma, where the heterogeneity of 
the disease may really require a “personalized therapy” in the 
presence of a lack of adequate asthma control with the current 
pharmacologic therapies. In effect, the current approach to 
asthma management and treatment as reported in the GINA 
guidelines is a traditional approach in the first four steps; the 
approach of “reactive medicine” is used. In GINA step 5, a 
“targeted medicine” approach is the recommended option, 
which is where omalizumab, a humanized monoclonal 
antibody that selectively targets immunoglobulin E (IgE), 
is positioned.7 In fact, nowadays the evolution from “empiri-
cal medicine” to “precision medicine” in several chronic 
diseases is highlighted. This evolution is present in asthma 
too, mainly in severe asthma, where costly treatments will 
find appropriate positioning.
The so-called “omics” sciences such as genomics and 
proteomics are providing new tools to facilitate discovery-
driven studies on new and reliable biomarkers that can 
Table 1 Main asthma phenotypes, according to clinical manifes-
tations, inducers/trigger factors and inflammatory pattern
Clinical or physiologic phenotypes
Onset of asthma (early vs late)
Severity (mild–moderate vs severe)
Airway obstruction (occasional vs persistent)
exacerbation-prone (occasional vs frequent)
Asthma in obese subjects
Phenotypes according to inducers and/or triggers
Allergic asthma
Occupational asthma
exercise-induced asthma
Aspirin-induced asthma
Asthma in smokers
Phenotypes according to the inflammatory pattern
eosinophilic asthma
Neutrophilic asthma
Mixed inflammatory asthma
Paucigranulocytic asthma
Note: Data from wenzel.6
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predict response to therapy, help identify patients who are 
more suitable for a given treatment and provide a focus for 
the development of targeted therapies.16 New treatments 
such as biological therapies are now available that modify 
specific pathogenic mechanisms based on precise genotype 
characterization in the individual patient. This represents the 
first step toward personalized therapy for asthma patients, 
especially for those with more severe disease.17,18
There is increasing awareness of the role of IgE in 
allergic asthma. Therefore, we undertook a review aimed 
at summarizing the current knowledge of the mechanisms 
and pathogenesis of severe asthma, with particular focus on 
examining the role of IgE and the biological rationale for 
targeting IgE in allergic asthma.
Biological rationale for IgE as 
a therapeutic target in allergic 
asthma
Over recent decades, the key role of IgE in the pathophysi-
ology of allergic asthma has been recognized.19 IgEs have 
been identified as central players of allergic asthma, regu-
lating a network that involves specific receptors expressed 
on a broad array of immune cells and also on airway tissue 
structural cells.
Membrane receptors for ige
The high-affinity IgE receptor (FcεRI) is constitutively 
expressed on mast cells and basophils as a tetrameric complex 
composed of an IgE-binding α subunit, a four-transmembrane-
spanning β subunit and two identical disulfide-linked γ sub-
units.20 Wan et al21 demonstrated that IgE binding to the 
FcεRI α chain involves the Cε3 domain pair of IgE, which 
is also the binding site for omalizumab.
In humans, a trimeric complex lacking the β chain 
(FcεRIαγ
2
) also exists and is expressed by the professional 
antigen-presenting cells (APCs) and a wide variety of other 
cell types, including airway smooth muscle cells (ASMCs) 
and airway epithelial cells (AECs) of asthmatic patients.22,23
The low-affinity IgE receptor (FcεRII or CD23) is 
transcribed in two spliced isoforms, CD23a and CD23b, 
with CD23a being constitutively expressed on B cells and 
CD23b, upon interleukin (IL)-4 activation, on several cell 
types, including APCs, eosinophils, neutrophils and human 
bronchial epithelial cells.24
IgE regulates the expression of both high- and low-affinity 
receptors. A direct correlation between total serum IgE levels 
and FcεRI surface expression has been reported for human 
basophils, monocytes and dendritic cells (DCs).25–27
Similarly, IgE binding to CD23 inhibits receptor cleav-
age by proteases, thus allowing the IgE–CD23 complex to 
stabilize on the cell surface.28 Conversely, the unoccupied 
membrane form of CD23 is highly susceptible to proteolytic 
cleavage,29 leading to the release of a free receptor known 
as soluble CD23 (sCD23), which retains the capability to 
bind IgE.
sCD23 and other two human soluble IgE receptors, 
namely, soluble FcεRI (sFcεRI) and galectin-3, represent 
additional elements of the IgE network.30
Biological functions of the ige network 
on mast cells and basophils
The ligation of allergen to FcεRI-bound IgE on mast cells 
and basophils initiates a signaling cascade leading to the 
release of preformed and de novo synthesized mediators. 
A classic “early-phase” reaction is characterized by vaso-
dilation, increased vascular permeability, upregulation of 
adhesion molecules and contraction of smooth muscle cells, 
whereas the “late-phase” reaction leads to the production of 
cytokines that orchestrate the recruitment and activation of 
several immune cells.31
Signaling events involved in regulating FcεRI-mediated 
mast cell and basophil activation and the role of these effector 
cells in the pathophysiology of asthma have been reviewed 
extensively.19,31,32 Notably, a positive-feedback regulation 
of FcεRI expression on mast cells and basophils is provided 
by monomeric IgE in the absence of allergen cross-linking 
(Box 1), whereas, upon receptor engagement, a negative-
feedback regulation is provided by receptor ubiquitination 
that represents a signal for endocytosis and lysosomal 
degradation of engaged receptor complexes.33
ige and the biological activities of DCs
DCs, typical of professional APCs, can provide all the known 
co-stimulatory signals required for activation of naive T cells. 
DCs are present in an extended and highly intricate network 
at the level of the respiratory mucosa; they can uptake inhal-
ant allergen molecules, process and transport them to the 
regional lymph nodes, where DCs can present the peptides 
to specific T cells. Among membrane receptors of DCs, the 
FcεRI mediates IgE-dependent allergen presentation.22,34
In addition to their constitutive presence within environ-
mentally accessible organs, eg, skin and mucosal tissues, 
FcεRI-expressing APCs circulate in peripheral blood and, 
upon allergen challenge, may enter sites of ongoing allergic 
inflammation, eg, airway walls. With low concentration of 
allergens within such tissues, the expression of FcεRI on 
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APCs by atopic individuals may critically promote allergen 
uptake, processing and presentation, thus ensuring allergen-
specific T-cell responses.19 FcεRI-IgE-dependent allergen 
presentation may hence critically lower the atopic individ-
ual’s threshold to mount allergen-specific T-cell responses. 
In fact, the targeting of allergens to FcεRI via IgE leads to 
a 1,000-fold increase in the activation of T cells and to the 
production of CCL28, a chemokine that selectively attracts 
T helper (Th) 2 lymphocytes.35,36 Consequently, such activa-
tion of allergen-specific Th cells may result in the perpetu-
ation of allergen-specific IgE production and, thus, of type 
I reactions and possibly even the induction of delayed-type 
hypersensitivity reactions in allergen-exposed tissues.34
The effect of the IgE network on DCs is still more com-
plex, taking into account that FcεRI on monocytes can lead 
to IL-10 production preventing their in vitro differentiation in 
DCs.37 This modulation of APC differentiation promotes a less 
efficient T-cell activation, suggesting a contribution of FcεRI 
in the downregulation of the inflammation. Furthermore, 
FcεRI is a negative regulator of plasmacytoid DC interferon-I 
production through the activation of immunoglobulin-like 
transcript 7, an inhibitory receptor bearing an immunoreceptor 
tyrosine-based activating motif-based activation motif.38
expression and putative functions of ige 
receptors on human eosinophils and 
macrophages
Human eosinophils develop as mature cells in the bone mar-
row, and they usually have a short (24–48-hour) lifespan 
in the blood. Under normal circumstances, these cells do 
not accumulate within peripheral tissues unless they are 
recruited locally by specific proinflammatory cytokines and 
chemokines. Early studies demonstrated that human blood 
eosinophils express mRNA for all chains (α, β and γ) of the 
high-affinity IgE receptor.39–41 In diseases associated with 
high IgE and eosinophilia, surface expression of the FcεRI 
has been detected in both blood and tissue eosinophils. 
However, the level of membrane expression is usually low, 
and its detection is often complicated by the presence of 
intracellular stores of the receptor. Human eosinophils also 
express FcεRII that, together with FcεRI, have been associ-
ated with the anti-parasitic function of these cells.39 Increased 
expression of either the high- or low-affinity IgE receptor 
on eosinophils has been associated with their recruitment in 
hypereosinophilic disorders.
Despite being fully saturated by IgE, the mechanisms of 
activation and the responses elicited by FcεRI engagement 
on eosinophils are still undefined. Studies in vitro failed to 
demonstrate degranulation of eosinophils by cross-linking of 
IgE on their surface.42 Thus, the real function of this receptor 
on human eosinophils still remains elusive.
Macrophages are ubiquitous cells developed by differen-
tiation and maturation of blood monocytes recruited within 
peripheral tissues. These cells play a primary role in innate 
immunity, regulating local tissue inflammation, injury and 
remodeling. IgE-mediated activation of macrophages through 
FcεRI has been demonstrated in a murine and human model 
of aortic aneurysm development.43
IgE activation of macrophages leads to the release of IL-6, 
MCP-1 and other proinflammatory cytokines, as well as to 
macrophage apoptosis.43 Furthermore, FcεRI stimulation 
promotes the generation of macrophage-like cells express-
ing the H1 receptor for histamine with enhanced histamine 
biosynthesis and histamine-mediated proinflammatory 
Box 1 ige and mast cell/basophil homeostasis
exposure to high levels of monomeric ige enhances FcεRi expression on basophils and mast cells27,73,74 that show an increased magnitude and 
sensitivity of responsiveness.
Moreover, IgE antibodies significantly affect murine mast cell survival and proliferation and promote cytokine production.75,76 Similarly, human 
monomeric ige induces histamine and leukotriene release by human lung mast cells.77
Mast cells that undergo ige-dependent FcεRi upregulation show an increased versatility, magnitude and sensitivity of responsiveness. Thus, the 
progressive accumulation of receptors at the cell surface contributes to the maintenance of a positive amplification loop.
However, Kawakami’s group demonstrated that there is a high variability among IgE molecules of different specificities with respect to the 
reported activities and designated as “highly cytokinergic” (HC) those IgE clones capable of inducing significant quantities of cytokines.78 Notably, 
HC ige clones can cross-react with multiple autoantigens and may promote a low level of FcεRi aggregation.78,79
Taken together, these findings provide a potential mechanism to explain the effects of HC IgE in the absence of the nominal allergen, whereby 
cross-linking of ige-occupied receptors would be induced by ubiquitous self-antigens. Furthermore, they provide the biological rationale 
for targeting ige in allergic asthma with agents such as omalizumab. with respect to the homeostatic effects of ige, the depletion of free 
ige by omalizumab results in the downregulation of FcεRi on basophils and mast cells, making those cells less sensitive to stimulation by 
incoming allergens.49,80 Moreover, ige neutralization abolishes the ability of monomeric ige to activate mast cell survival, proliferation and 
cytokine production.
Abbreviation: ige, immunoglobulin e.
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properties.44 Supporting these in vitro findings, high numbers 
of histamine H1 receptor-expressing CD68+ macrophages 
were detected in the dermis of atopic dermatitis skin lesions.44 
These results support the hypothesis of a functionally active 
FcεRI expression on human macrophages involved in the pro-
inflammatory and tissue remodeling activity of these cells.
ige and smooth muscle cell function
ASMCs are one type of the main structural cells of the 
airway walls, considered for many years only as contract-
ing elements involved in bronchoconstriction during acute 
exacerbations of asthma.
The activation of ASMCs is a crucial step of asthma 
pathophysiology. In fact, smooth muscle thickening in 
asthma is a consequence of both hypertrophy and hyperplasia, 
both of which correlate with asthma severity.45 In addition to 
their physical properties, ASMCs can participate in inflam-
matory processes through the release of a variety of inflam-
matory cytokines and chemokines, modulating the initiation, 
amplification and perhaps resolution of airway inflammation. 
Upon stimulation or interaction with immune cells, ASMCs 
produce and secrete extracellular matrix proteins that are key 
factors actively involved in the remodeling of airway walls. 
The activation of ASMCs is the consequence not only of the 
direct effect on these cells by preformed mediators released 
by mast cells and basophils during the acute allergic reac-
tion but also through the involvement of IgE fixed on their 
surface, in that they express FcεRI.23 The activation of FcεRI 
on ASMCs suggests a critical yet almost completely ignored 
network, which may modulate the function of this type of 
cells in allergic asthma.
The major effect of IgE on remodeling is mediated via 
FcεRI and explains the release of collagen type-I and -III by 
ASMCs, as well as their proliferation.46
ige network and AeC functions
The epithelial airway tract and allergen-specific IgE are 
considered essential regulators of inflammatory responses 
to allergens. Indeed, the low-affinity IgE receptor, CD23, 
is expressed on AECs and acts as a transporter of IgE or 
IgE–allergen complexes across the polarized airway mucosal 
barrier both in vitro and in vivo.47,48
The mechanism of transport mediated by CD23 implies 
that the IgE produced locally by B lymphocytes is recog-
nized by the receptor on the apical membrane of AECs and 
released into the lumen, resulting in binding inhaled allergens 
to form immune complexes. They would then be transported 
in the opposite direction where they could engage the FcεRI 
expressed by sensitized mast cells promoting their degranula-
tion and be captured and processed by DCs, thus facilitating 
presentation to Th2 cells. Since AECs are the first cells to 
come into contact with the allergen assumed by inhalation, 
this mechanism plays a pivotal role in the initiation and 
development of airway allergic inflammation.47
In summary, targeting the inflammatory and allergic 
process can be considered a valid approach to control 
the symptoms of severe allergic asthma. In this respect, 
omalizumab selectively binds free IgE molecules, blocking 
the binding site for both FcεRI and CD23, modulating and 
acting upstream of the IgE network and slowing or preventing 
the allergic inflammatory cascade.49 A schematic representa-
tion of the biological function of the IgE network and the 
possible effects of omalizumab is shown in Figure 1. Thus, 
treatment with omalizumab provides the unique opportunity 
of blocking both the allergen-specific airway response and 
the initiation and development of chronic airway allergic 
inflammation.
Targeting IgE in allergic asthma: 
from theory to practical application
Omalizumab is currently the only available IgE-targeted 
therapeutic agent, approved for patients with severe allergic 
asthma and high IgE blood levels.
Initial clinical studies evaluating the efficacy of omali-
zumab in asthma showed that this anti-IgE monoclonal anti-
body significantly inhibited early- and late-phase asthmatic 
reactions, triggered by inhaled allergens.50 Subsequently, a 
series of randomized controlled trials have shown that add-on 
treatment with omalizumab is very effective in reducing 
respiratory symptoms and especially asthma exacerbations, 
hospitalizations, emergency room visits and consump-
tion of oral corticosteroids in patients with moderate-to- 
severe asthma.51–53
Specifically, omalizumab has been shown to significantly 
decrease severe disease exacerbations in subjects with 
uncontrolled allergic asthma.54–56 Furthermore, omalizumab 
as add-on therapy in patients with moderate-to-severe asthma 
and concomitant rhinitis markedly improved both Asthma 
Quality-of-Life Questionnaire (AQLQ) and Rhinitis Quality-
of-Life Questionnaire (RQLQ) scores.57 These results are 
very important because of the high relevance of allergic 
rhinitis as one of the most prevalent asthma comorbidities.
The Investigation of Omalizumab in Severe Asthma 
Treatment (INNOVATE) study was a pivotal study in 419 
allergic subjects with uncontrolled severe asthma, character-
ized by recurrent disease exacerbations and marked bronchial 
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obstruction (baseline FEV
1
 $40% –,80% predicted). 
Asthma exacerbations, emergency visits and requirements of oral 
corticosteroids significantly decreased in patients undergoing 
28-week add-on anti-IgE therapy with omalizumab, compared 
with placebo.58 These findings have been confirmed in 850 asth-
matic patients with a wide age range (12–75 years), who under-
went a comparative evaluation of omalizumab versus placebo after 
48 weeks of add-on treatment, in which omalizumab significantly 
lowered asthma symptoms and exacerbations and also reduced 
the daily need for short-acting rescue bronchodilators.59 Treat-
ment with omalizumab has also been shown to be accompanied 
by relevant improvements in quality of life, asthma symptoms and 
peak expiratory flow.58 Of particular interest, 60 weeks of add-on 
treatment with omalizumab significantly improved asthma 
control and prevented seasonal exacerbations in 419 subjects 
with moderate-to-severe persistent allergic asthma, including 
inner city children, adolescents and young adults.60 The data 
from placebo-controlled trials have been further validated by 
real-life studies performed worldwide and recently systematically 
reviewed by Abraham et al.61
Data from completed clinical studies of 1–4 years 
duration and involving .7,500 patients with asthma, rhinitis 
or related conditions, as well as post-marketing safety data, 
have confirmed a high level of safety and tolerability with 
omalizumab treatment,62,63 with a placebo-like tolerability 
profile and no increased risk of omalizumab-related hyper-
sensitivity reactions, immune system abnormalities, cardio-
vascular events, cancer, parasitic infections or other relevant 
diseases. Furthermore, no measurable anti-omalizumab 
antibodies were produced in patients treated up to 4 years. 
?????????????
????????????
?????????????????????????????????????????????????????????
?????????????????????????
???????????
?????????????????????
????
???
???????????????? ????????
??????????
??????????
?
???
?????????????????????
??ε??
??ε??????????
Figure 1 Schematic representation of the biological functions of the ige network, which are inhibited by omalizumab.
Notes: Republished with permission of J Allergy Clin Immunol Pract, from Omalizumab in asthma: an update on recent developments. Humbert M, Busse w, Hanania NA, et al. 
vol 2(5). Copyright 2014; permission conveyed through Copyright Clearance Center, inc.72
Abbreviations: ige, immunoglobulin e; DCs, dendritic cells; Th, T helper; iL, interleukin.
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In essence, the role of omalizumab as the only current agent 
with a specific target that functions as a stratified or multi-
targeted therapy and has been demonstrated to be safe and 
effective in the context of currently recommended treatments 
makes it unique in the treatment of allergic asthma, the most 
easily recognized of the “asthma phenotypes”.
Appropriate patient selection is a key aspect for successful 
anti-IgE therapy of severe asthma, with the best therapeutic 
results likely to be achieved by treating severe, inadequately 
controlled and oral steroid-dependent asthmatics experi-
encing frequent disease exacerbations. Identifying reliable 
biomarkers that can predict response to therapy and help 
define candidate patients more suited for a given treatment 
is an important and ongoing focus in developing biological 
therapies, such as omalizumab, which can modify specific 
pathogenic mechanisms based on precise genotype character-
ization in the individual patient. In this regard, the EXTRA 
study has demonstrated that high baseline values of peripheral 
blood eosinophils can be regarded as a reliable biomarker 
of Th2 cell-driven allergic inflammation in patients with 
allergic asthma, especially in association with high levels of 
fractional exhaled nitric oxide (FeNO) and serum periostin.64 
These three biomarkers make it possible to predict a positive 
therapeutic response to omalizumab in terms of decreasing 
asthma exacerbations. Furthermore, omalizumab has been 
shown to be associated with significant decreases in sputum 
and peripheral blood eosinophils in patients with asthma,65,66 
supporting the role of omalizumab in reducing inflammatory 
activity in the airways of patients with allergic asthma.
The duration of anti-IgE treatment is also an important 
aspect to consider. The mechanism of action of omalizumab, 
based on competitive binding to the Cε3 domain of the con-
stant fragment of IgE, would suggest that this drug should 
be used according to a life long schedule in order to block 
IgE functions and to avoid potential symptoms relapses and 
exacerbations.67–69 However, there are some indications that 
improvements in asthma symptoms and lung function may 
persist for at least 3 years after discontinuation of anti-IgE 
therapy,70,71 suggesting that anti-IgE therapy could modify 
the natural history of moderate-to-severe uncontrolled asthma 
in some patients, perhaps due in part to a modulatory action 
of omalizumab on bronchial remodeling.
Discussion and conclusion
IgE-mediated allergic asthma still represents a majority of 
patients with asthma. The recent GINA report redrew the 
definition of asthma, emphasizing its heterogeneity and the 
relevance of disease phenotypes, while recognizing specific 
biological pathways as clinical features to be considered in 
the management of severe or difficult-to-treat asthma. Indeed, 
in GINA step 5, anti-IgE treatment with omalizumab is the 
recommended option when moderate or severe allergic asthma 
is uncontrolled on step 4 treatment.7 To better understand 
the mechanisms regulating the IgE-mediated mechanisms 
in allergic asthma, we have herein reviewed the features and 
functions of IgE receptors and the interactions with differ-
ent cellular components, such as mast cells and basophils or 
eosinophils, epithelial cells or smooth muscle cells. These last 
cells proliferate as a consequence of IgE-driven inflammation, 
thus leading to exacerbations of respiratory symptoms, airway 
remodeling and subsequently affecting pulmonary function.
As a better understanding of the molecular mechanisms 
and pathogenesis of the disease processes underlying aller-
gic asthma, additional agents that inhibit specific pathways 
will likely be developed, leading to further reductions in the 
burden of asthma.
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